Lupin Limited shareholders approved a final dividend of ₹18 per equity share for the financial year ended March 31, 2026, alongside the reappointment of key board members and auditors, during its 44th Annual General Meeting (AGM) held on August 04, 2026. The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), concluded with all five proposed ordinary resolutions passing with the requisite majority, signaling strong shareholder alignment on governance and capital distribution.

The AGM was chaired by Manju D. Gupta, Chairperson, and attended by 77 members through the VC/OAVM facility provided by National Securities Depository Limited (NSDL). Key executives present included Vinita Gupta, Chief Executive Officer; Nilesh D. Gupta, Managing Director; and Ramesh Swaminathan, Executive Director and Global CFO. Independent Director Jeffrey Kindler was absent due to personal exigency. The Statutory Auditors, B S R & Co. LLP, Secretarial Auditors Makarand M. Joshi & Co., and Cost Auditor Suresh D. Shenoy were also present. Saurabh Agarwal of Makarand M. Joshi & Co. served as the Scrutinizer for the remote e-voting process.

Shareholders voted overwhelmingly in favor of adopting the Audited Standalone and Consolidated Financial Statements for FY26. The resolution received 99.55% support from total votes polled, with promoter group voting standing at 100% in favor. Public institutions contributed significantly to the turnout, polling 91.79% of their outstanding shares, while public non-institutions polled 1.15%. No invalid votes were recorded across any category.

The declaration of a final dividend of ₹18 per equity share for FY26 achieved near-unanimous support, securing 100% approval from votes polled. Promoter and promoter group shares voted entirely in favor, as did all public institution votes. Only 664 votes against were cast by public non-institutions, representing a negligible fraction of the total poll. This dividend payout reinforces the company’s commitment to returning value to shareholders following the completion of its fiscal year.

Governance resolutions also passed smoothly. Nilesh D. Gupta was reappointed as a Director liable to retire by rotation, receiving 99.81% support from votes polled. Deloitte Haskins & Sells Chartered Accountants LLP was appointed as the Statutory Auditors, garnering 99.98% support. Additionally, the remuneration of the Cost Auditor for FY27 was ratified with 100% support from votes polled. The remote e-voting period had commenced on July 31, 2026, and concluded on August 03, 2026, with voting rights restricted for Foreign Portfolio Investors who failed to submit additional disclosures as per SEBI guidelines.

Lupin has received approval from the U.S. Food and Drug Administration (FDA) for Diazepam Injection USP, marking a notable regulatory milestone for the pharmaceutical company. This approval adds to Lupin's growing portfolio of products in the U.S. market.

Regulatory Approval Details

The following key details summarize the approved product:

Significance for U.S. Market Presence

The U.S. FDA approval of Diazepam Injection USP reflects Lupin's ongoing efforts to strengthen its generics portfolio in one of the world's largest pharmaceutical markets. Diazepam is a well-established pharmaceutical compound, and this approval enables Lupin to participate in the injectable segment of the U.S. market. The development represents continued regulatory progress for the company's U.S. business operations.